To further explore the synergy between IFN gene therapy and adoptive T-cell transfer in a clinically relevant model, we generated T cells expressing a previously described second generation (2 G) CAR targeting the mouse CD19 (CART19 cells) and incorporating the CD28 endocostimulatory domain17, and treated mice injected with the parental (OVA-negative) ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.